These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 25733532)

  • 1. The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials.
    Ricotti V; Ridout DA; Pane M; Main M; Mayhew A; Mercuri E; Manzur AY; Muntoni F;
    J Neurol Neurosurg Psychiatry; 2016 Feb; 87(2):149-55. PubMed ID: 25733532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantifying Variability in Motor Function in Duchenne Muscular Dystrophy: UK Centiles for the NorthStar Ambulatory Assessment, 10 m Walk Run Velocity and Rise from Floor Velocity in GC Treated Boys.
    Stimpson G; Ridout D; Wolfe A; Milev E; O'Reilly E; Manzur A; Sarkozy A; Muntoni F; Cole TJ; Baranello G;
    J Neuromuscul Dis; 2024; 11(1):153-166. PubMed ID: 37980680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Categorising trajectories and individual item changes of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy.
    Muntoni F; Domingos J; Manzur AY; Mayhew A; Guglieri M; ; Sajeev G; Signorovitch J; Ward SJ
    PLoS One; 2019; 14(9):e0221097. PubMed ID: 31479456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial.
    Mah JK; Clemens PR; Guglieri M; Smith EC; Finkel RS; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; McDonald CM; Damsker JM; Schwartz BD; Mengle-Gaw LJ; Jackowski S; Stimpson G; Ridout DA; Ayyar-Gupta V; Baranello G; Manzur AY; Muntoni F; Gordish-Dressman H; Leinonen M; Ward LM; Hoffman EP; Dang UJ;
    JAMA Netw Open; 2022 Jan; 5(1):e2144178. PubMed ID: 35076703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural History of Steroid-Treated Young Boys With Duchenne Muscular Dystrophy Using the NSAA, 100m, and Timed Functional Tests.
    Miller NF; Alfano LN; Iammarino MA; Connolly AM; Moore-Clingenpeel M; Powers BR; Tsao CY; Waldrop MA; Flanigan KM; Mendell JR; Lowes LP
    Pediatr Neurol; 2020 Dec; 113():15-20. PubMed ID: 32979653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of disease progression and genetic correlation in ambulatory Iranian boys with Duchenne muscular dystrophy.
    Zamani G; Hosseinpour S; Ashrafi MR; Mohammadi M; Badv RS; Tavasoli AR; Akbari MG; Bereshneh AH; Malamiri RA; Heidari M
    BMC Neurol; 2022 May; 22(1):162. PubMed ID: 35501714
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Muntoni F; Signorovitch J; Sajeev G; Lane H; Jenkins M; Dieye I; Ward SJ; McDonald C; Goemans N; Niks EH; Wong B; Servais L; Straub V; Guglieri M; de Groot IJM; Chesshyre M; Tian C; Manzur AY; Mercuri E; Aartsma-Rus A;
    Neurology; 2023 Apr; 100(15):e1540-e1554. PubMed ID: 36725339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotype characterization and delayed loss of ambulation by glucocorticoids in a large cohort of patients with Duchenne muscular dystrophy.
    Zhang S; Qin D; Wu L; Li M; Song L; Wei C; Lu C; Zhang X; Hong S; Ma M; Wu S;
    Orphanet J Rare Dis; 2021 Apr; 16(1):188. PubMed ID: 33910603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study.
    Bello L; Morgenroth LP; Gordish-Dressman H; Hoffman EP; McDonald CM; Cirak S;
    Neurology; 2016 Jul; 87(4):401-9. PubMed ID: 27343068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Long-term Ambulatory Function in Patients with Duchenne Muscular Dystrophy Treated with Eteplirsen and Matched Natural History Controls.
    Mendell JR; Khan N; Sha N; Eliopoulos H; McDonald CM; Goemans N; Mercuri E; Lowes LP; Alfano LN;
    J Neuromuscul Dis; 2021; 8(4):469-479. PubMed ID: 33523015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study.
    Mazzone E; Vasco G; Sormani MP; Torrente Y; Berardinelli A; Messina S; D'Amico A; Doglio L; Politano L; Cavallaro F; Frosini S; Bello L; Bonfiglio S; Zucchini E; De Sanctis R; Scutifero M; Bianco F; Rossi F; Motta MC; Sacco A; Donati MA; Mongini T; Pini A; Battini R; Pegoraro E; Pane M; Gasperini S; Previtali S; Napolitano S; Martinelli D; Bruno C; Vita G; Comi G; Bertini E; Mercuri E
    Neurology; 2011 Jul; 77(3):250-6. PubMed ID: 21734183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease progression modeling of the North Star Ambulatory Assessment for Duchenne Muscular Dystrophy.
    Hibma JE; Jayachandran P; Neelakantan S; Harnisch LO
    CPT Pharmacometrics Syst Pharmacol; 2023 Mar; 12(3):375-386. PubMed ID: 36718719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peak functional ability and age at loss of ambulation in Duchenne muscular dystrophy.
    Zambon AA; Ayyar Gupta V; Ridout D; Manzur AY; Baranello G; Trucco F; Muntoni F;
    Dev Med Child Neurol; 2022 Aug; 64(8):979-988. PubMed ID: 35385138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of Loss of Ambulation in Duchenne Muscular Dystrophy: A Systematic Review and Meta-Analysis.
    Landfeldt E; Alemán A; Abner S; Zhang R; Werner C; Tomazos I; Ferizovic N; Lochmüller H; Kirschner J
    J Neuromuscul Dis; 2024; 11(3):579-612. PubMed ID: 38669554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fractures and Linear Growth in a Nationwide Cohort of Boys With Duchenne Muscular Dystrophy With and Without Glucocorticoid Treatment: Results From the UK NorthStar Database.
    Joseph S; Wang C; Bushby K; Guglieri M; Horrocks I; Straub V; Ahmed SF; Wong SC;
    JAMA Neurol; 2019 Jun; 76(6):701-709. PubMed ID: 30855644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors Associated With Early Motor Function Trajectories in DMD After Glucocorticoid Initiation: Post Hoc Analysis of the FOR-DMD Trial.
    Schiava M; McDermott MP; Broomfield J; Abrams KR; Mayhew AG; McDonald CM; Martens WB; Gregory SJ; Griggs RC; Guglieri M;
    Neurology; 2024 May; 102(10):e209206. PubMed ID: 38710006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delayed onset of ambulation in boys with Duchenne muscular dystrophy: Potential use as an endpoint in clinical trials.
    Gissy JJ; Johnson T; Fox DJ; Kumar A; Ciafaloni E; van Essen AJ; Peay HL; Martin A; Lucas A; Finkel RS;
    Neuromuscul Disord; 2017 Oct; 27(10):905-910. PubMed ID: 28739181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moving towards meaningful measurement: Rasch analysis of the North Star Ambulatory Assessment in Duchenne muscular dystrophy.
    Mayhew A; Cano S; Scott E; Eagle M; Bushby K; Muntoni F;
    Dev Med Child Neurol; 2011 Jun; 53(6):535-42. PubMed ID: 21410696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detecting meaningful change using the North Star Ambulatory Assessment in Duchenne muscular dystrophy.
    Mayhew AG; Cano SJ; Scott E; Eagle M; Bushby K; Manzur A; Muntoni F;
    Dev Med Child Neurol; 2013 Nov; 55(11):1046-52. PubMed ID: 23909763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring the relationship between North Star Ambulatory Assessment and Health Utilities Index scores in Duchenne muscular dystrophy.
    Audhya I; Rogula B; Szabo SM; Feeny D; Bolatova T; Gooch K
    Health Qual Life Outcomes; 2023 Jul; 21(1):76. PubMed ID: 37468890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.